Sunmax Biotechnology Statistics
Total Valuation
Sunmax Biotechnology has a market cap or net worth of TWD 15.00 billion. The enterprise value is 14.56 billion.
Market Cap | 15.00B |
Enterprise Value | 14.56B |
Important Dates
The last earnings date was Monday, November 11, 2024.
Earnings Date | Nov 11, 2024 |
Ex-Dividend Date | Jul 17, 2024 |
Share Statistics
Sunmax Biotechnology has 54.46 million shares outstanding. The number of shares has decreased by -0.11% in one year.
Current Share Class | n/a |
Shares Outstanding | 54.46M |
Shares Change (YoY) | -0.11% |
Shares Change (QoQ) | +0.01% |
Owned by Insiders (%) | 10.25% |
Owned by Institutions (%) | 6.96% |
Float | 34.10M |
Valuation Ratios
The trailing PE ratio is 21.49.
PE Ratio | 21.49 |
Forward PE | n/a |
PS Ratio | 8.60 |
PB Ratio | 10.98 |
P/TBV Ratio | n/a |
P/FCF Ratio | 31.50 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.44, with an EV/FCF ratio of 30.56.
EV / Earnings | 20.83 |
EV / Sales | 8.35 |
EV / EBITDA | 14.44 |
EV / EBIT | 15.93 |
EV / FCF | 30.56 |
Financial Position
The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.11.
Current Ratio | 3.40 |
Quick Ratio | 2.46 |
Debt / Equity | 0.11 |
Debt / EBITDA | 0.15 |
Debt / FCF | 0.32 |
Interest Coverage | 149.96 |
Financial Efficiency
Return on equity (ROE) is 53.12% and return on invested capital (ROIC) is 38.71%.
Return on Equity (ROE) | 53.12% |
Return on Assets (ROA) | 29.90% |
Return on Capital (ROIC) | 38.71% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.91 |
Inventory Turnover | 2.79 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.00% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +39.00% |
50-Day Moving Average | 268.62 |
200-Day Moving Average | 261.37 |
Relative Strength Index (RSI) | 53.57 |
Average Volume (20 Days) | 28,540 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sunmax Biotechnology had revenue of TWD 1.74 billion and earned 698.95 million in profits. Earnings per share was 12.82.
Revenue | 1.74B |
Gross Profit | 1.43B |
Operating Income | 913.53M |
Pretax Income | 945.34M |
Net Income | 698.95M |
EBITDA | 977.17M |
EBIT | 913.53M |
Earnings Per Share (EPS) | 12.82 |
Balance Sheet
The company has 603.50 million in cash and 154.77 million in debt, giving a net cash position of 448.73 million or 8.24 per share.
Cash & Cash Equivalents | 603.50M |
Total Debt | 154.77M |
Net Cash | 448.73M |
Net Cash Per Share | 8.24 |
Equity (Book Value) | 1.37B |
Book Value Per Share | 25.09 |
Working Capital | 600.84M |
Cash Flow
In the last 12 months, operating cash flow was 550.17 million and capital expenditures -73.80 million, giving a free cash flow of 476.37 million.
Operating Cash Flow | 550.17M |
Capital Expenditures | -73.80M |
Free Cash Flow | 476.37M |
FCF Per Share | 8.75 |
Margins
Gross margin is 81.97%, with operating and profit margins of 52.40% and 40.09%.
Gross Margin | 81.97% |
Operating Margin | 52.40% |
Pretax Margin | 54.23% |
Profit Margin | 40.09% |
EBITDA Margin | 56.05% |
EBIT Margin | 52.40% |
FCF Margin | 27.32% |
Dividends & Yields
This stock pays an annual dividend of 11.00, which amounts to a dividend yield of 3.99%.
Dividend Per Share | 11.00 |
Dividend Yield | 3.99% |
Dividend Growth (YoY) | 15.79% |
Years of Dividend Growth | 5 |
Payout Ratio | 85.71% |
Buyback Yield | 0.11% |
Shareholder Yield | 4.10% |
Earnings Yield | 4.65% |
FCF Yield | 3.17% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | n/a |